FDA’s New Manufacturing Proposal Could Redefine What Counts as One Site
The FDA published the proposed rule in the Federal Register on July 13, 2026. The agency will accept comments until September 11, 2026. Under the proposal, a distributed manufacturing establishment, or DME, would include a central hub and one or more distributed manufacturing units, or DMUs. A single quality unit at the hub would oversee the network through a unified pharmaceutical quality system.
The pathway would not apply to every multisite manufacturer. Instead, the units must operate under one management structure, manufacture the same drugs, and remain equivalent in design and operation.
Why Distributed Manufacturing Matters Most for Cell and Gene Therapies
The model may carry particular value for cell and gene therapies. Autologous cell therapies begin with material collected from an individual patient and return as a patient-specific dose. Therefore, long transport routes to centralized plants can add time and logistical pressure.
Jason Bock, founder and CEO of CTMC, argues that manufacturers should build these networks around patient proximity rather than centralized scale. However, this view represents an industry interpretation of the proposal. The FDA has proposed a broader registration framework for qualifying distributed manufacturers.
One FDA Registration Could Hide a Much Bigger Quality Challenge
A single registration cannot create a single quality system by itself. Manufacturers must establish clear authority for deviations, CAPAs, batch disposition, training, supplier controls, complaints, recalls, and change management across every DMU.
Moreover, the hub must detect network-wide signals. For example, similar deviations at separate units may reveal one shared process weakness. The quality unit must therefore trend events across the full network instead of reviewing each site in isolation.
Distributed Manufacturing Raises New Validation and Data Integrity Risks
Equivalence will become a central validation question. Companies must show that equipment, automation software, critical process parameters, analytical methods, utilities, environmental controls, material flows, data architecture, and operator qualifications remain sufficiently consistent.
Data integrity also becomes a network-level responsibility. The hub needs reliable access to records, audit trails, master data, user permissions, and synchronized timestamps. In addition, companies need controlled procedures for network failures, delayed data transfer, system recovery, and continued manufacturing during an outage.
What FDA Inspectors May Expect From Every Manufacturing Unit
If finalized, the proposal would simplify how qualifying networks update registration when they add, remove, or relocate a DMU. Still, relocation involves more than changing an address. It may affect utilities, calibration, environmental conditions, connectivity, qualification status, and material flow.
Consequently, manufacturers should assess quality governance, define equivalence criteria, design a platform-level validation strategy, and confirm escalation and batch-release authority before the rule becomes final. Inspectors may also expect evidence of site-specific qualification, network-wide deviation trending, traceable patient-specific doses, controlled data flows, business continuity, and disaster recovery. Ultimately, one registration will only work when the entire network can demonstrate one consistent state of control.
Managing a distributed manufacturing network as one establishment requires more than aligned registration; it requires a Quality Management System that connects deviations, CAPA, change control, batch review and audit readiness across every unit. Zamann Pharma’s Quality Management System support helps pharmaceutical teams strengthen these controls and maintain consistent GMP oversight as their operating models evolve.
Source: Pharmtech.Com